- With over 200 million people, Brazil is Latin America´s largest addressable
medical cannabis market, with the potential to reach USD$1.4 billion in annual revenue (Source: New
- In partnership with leading medical cannabis patient
association in Brazil, a child
with epilepsy becomes first Brazilian patient to receive Khiron
medical cannabis product
- Khiron plans to expand Zerenia™ vertically integrated clinic
model into Brazil, increasing
patient access to affordable, high-quality medical cannabis
TORONTO, July 2, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated medical cannabis leader with core operations
in Latin America and Europe, is pleased to announce it has
successfully completed its first sale of medical cannabis product
in Brazil. Leveraging production,
distribution, and clinical assets in Latin America, along with marketing agreements
with leading pharmaceutical distributors, Khiron plans to expand
its presence in Brazil, a market
of over 200 million people.
"Our initial export to the Brazilian market represents an
important first step toward opening a large, underserved market
where patients face high barriers to access. By providing patients
with affordable high-quality products, and an unparalleled patient
experience, we see an opportunity to disrupt the Brazilian market
and deliver on our mission of improving patients lives.
Khiron is already treating thousands of patients in
Colombia, Peru, UK and Germany, with positive outcomes. In due
course, we plan to bring our successful Zerenia clinic model to
Brazil, as we have done in
Peru and Colombia," comments Alvaro Torres, CEO and Director.
Through the Company´s strategic alliance with CANNAB, a patient
association that connects physicians, patients, academic
institutions, and suppliers, a three-year old child from
Salvador de Bahia suffering from
epilepsy has received six units of Khiron high-CBD 100mg/50ml
extract. The importation of Khiron's medical cannabis on behalf of
the patient was authorized by ANVISA (the Brazilian National Health
Surveillance Agency). The Company plans to collaborate with CANNAB
to continue offering its medical products to many more patients.
CANNAB expects to help over 1,200 new patients gain access to
medical cannabis products during 2021. According to Prohibition
Partners, the Brazilian medical cannabis user base could reach
close to 3 million people in the next few years.
The Company has also established two partnerships in
Brazil to increase product
awareness and medical cannabis education for health care providers
across the country. As previously announced, Khiron has an
exclusive agreement with Medlive, a pharmaceutical and health
products distributor with a network of over 3,000 clinics and
hospitals in southern Brazil. In
addition, the Company has signed a marketing contract with TAIMIN,
a leading medical distributor focused on Rio de Janeiro, Sao
Paulo and northern Brazil.
Together, the two agreements provide broad regional coverage across
Brazil and are intended to drive
sales by expanding Khiron's network of prescribing physicians. The
Company is also in discussion with several medical clinics as it
seeks to expand its clinic model into Brazil.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated medical cannabis company with core operations
in Latin America and Europe. Leveraging wholly-owned medical health
centres and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and agricultural infrastructure to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Brazil,
Germany and the UK, and is
positioned to commence sales in Mexico in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
SOURCE Khiron Life Sciences Corp.